沛嘉醫療-B(09996.HK)Syphonet取栓支架註冊申請獲藥監局批准
沛嘉醫療-B(09996.HK)公布,集團於2月11日收到國家藥監局對Syphonet取栓支架(先前英文名為
Shenyi)註冊申請的批准,使其成為集團第11個獲國家藥監局批准的神經介入產品。
Syphonet取栓支架是由公司全資附屬加奇生物所開發的技術領先產品,該產品的獨特遠端抓捕籃設計,能有效防止碎栓逃逸,有助於血栓的清除。支架設計具有優化的徑向支撐力,即使在彎曲血管中也能保持完整管腔。支架通體顯影,全程可視化操作,為術者提供良好的視覺反饋。
Syphonet取栓支架提供多種規格,全系列兼容0.017in微導管。良好的兼容性將提高到位成功率,減少手術的時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.